U.S. biotech CEO explains why he chose Hong Kong for primary listing

Remo Moomiaie-Qajar, CEO of San Diego-based Axiom Biosciences, discusses the "contrarian" strategy of making Hong Kong the primary listing destination before seeking a listing on the Nasdaq. Despite geopolitical tensions, the CEO said the company plans to leverage Hong Kong’s sophisticated biotech investor base and the "unprecedented speed" of China's clinical trial networks.